{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:27:34Z","timestamp":1792758454486,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ygyno.2016.06.013","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T13:24:50Z","timestamp":1467033890000},"page":"597-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited"],"prefix":"10.1016","volume":"142","clinical-trial-number":[{"clinical-trial-number":"nct01844986","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02477644","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Beyhan","family":"Ataseven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Chiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.06.013_bb0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2016.06.013_bb0010","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0020-7292(06)60032-5","article-title":"Carcinoma of the fallopian tube. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2016.06.013_bb0020","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0025","article-title":"Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV","author":"Ataseven","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0030","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.1999.17.3.767","article-title":"Natural history of stage IV epithelial ovarian cancer","volume":"17","author":"Bonnefoi","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygyno.2006.10.055","article-title":"Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system","volume":"105","author":"Aletti","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0040","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/gyno.2001.6172","article-title":"Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study","volume":"81","author":"Akahira","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"26","author":"Winter","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2176\/nmc.48.57","article-title":"Treatment and prognosis of brain metastases from gynecological cancers","volume":"48","author":"Ogawa","year":"2008","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1525-1438.2003.13054.x","article-title":"Distant metastases in ovarian carcinoma","volume":"13","author":"Cormio","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0060","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1097-0142(19871001)60:7<1561::AID-CNCR2820600725>3.0.CO;2-V","article-title":"Distant metastases in epithelial ovarian carcinoma","volume":"60","author":"Dauplat","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0065","series-title":"Histological Typing of Ovarian Tumors","author":"Serov","year":"1973"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0090-8258(76)90002-0","article-title":"Presentation of therapeutic results in carcinoma of the female pelvis: experience of the annual report on the results of treatment in carcinoma of the uterus, vagina, and ovary","volume":"4","author":"Kottmeier","year":"1976","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000675","article-title":"Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian, fallopian tube, and primary peritoneal cancer","author":"Rosendahl","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5468\/ogs.2015.58.2.124","article-title":"Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification","volume":"58","author":"Paik","year":"2015","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1097-0142(197803)41:3<919::AID-CNCR2820410320>3.0.CO;2-A","article-title":"Inguinal node metastases","volume":"41","author":"Zaren","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0095","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(197710)40:4<1444::AID-CNCR2820400414>3.0.CO;2-I","article-title":"Lymphangiography in patients with ovarian epithelial cancer: an evaluation of 289 consecutive cases","volume":"40","author":"Musumeci","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/IGC.0b013e3181c443ba","article-title":"Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications","volume":"20","author":"Heitz","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000826","article-title":"Impact of abdominal wall metastases on prognosis in ovarian cancer","author":"Ataseven","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0110","first-page":"107","article-title":"Carcinoma of the ovary","volume":"6","author":"Heintz","year":"2001","journal-title":"J Epidemiol Biostat"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0120","article-title":"What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer?","author":"Chiva","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0046-8177(88)80316-2","article-title":"Distribution of disease at autopsy in 100 women with ovarian cancer","volume":"19","author":"Dvoretsky","year":"1988","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2015.05.007","article-title":"The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer","volume":"138","author":"Raban","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2016.03.012","article-title":"Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer","author":"Prader","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0140","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000680","article-title":"Role of video-assisted thoracoscopy in advanced ovarian cancer: a literature review","author":"Di Guilmi","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0145","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ygyno.2009.12.008","article-title":"Does the use of diagnostic PET\/CT cause stage migration in patients with primary advanced ovarian cancer?","volume":"116","author":"Risum","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0150","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ygyno.2013.09.024","article-title":"Preoperative 18F-FDG PET\/CT in the management of advanced epithelial ovarian cancer","volume":"131","author":"Fruscio","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2012.04.023","article-title":"FDG PET\/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread","volume":"126","author":"Hynninen","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A randomized study of screening for ovarian cancer: a multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0165","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0170","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0175","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0180","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0190","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ygyno.2014.01.028","article-title":"TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer","volume":"132","author":"Zhang","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0195","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju048","article-title":"Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples","volume":"106","author":"Riester","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0200","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-14-0445","article-title":"Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer","volume":"20","author":"Tucker","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0205","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0210","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0215","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0220","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0225","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0230","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/bjc.2015.97","article-title":"Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients","volume":"112","author":"Mizuno","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0235","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ygyno.2012.05.001","article-title":"Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma","volume":"126","author":"Hyman","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0240","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/gyno.1998.5145","article-title":"Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer","volume":"72","author":"Bristow","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2016.05.021","article-title":"The revised 2014 FIGO staging system for epithelial ovarian cancer: is a subclassification into FIGO stage IVA and IVB justified?","author":"Ataseven","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0250","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0255","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ejca.2012.01.031","article-title":"Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?","volume":"48","author":"Trope","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0260","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1245\/s10434-010-0964-9","article-title":"Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)","volume":"17","author":"Wimberger","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0265","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0270","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0275","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0280","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/gyno.1996.4550","article-title":"Stage IV ovarian cancer: impact of surgical debulking","volume":"64","author":"Curtin","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0290","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1245\/s10434-011-2100-x","article-title":"Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer","volume":"19","author":"Rauh-Hain","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0295","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","article-title":"Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach","volume":"94","author":"Chi","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0300","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0305","unstructured":"Janco JMT, Glaser G, Kim B, McGree ME, Weaver AL, Cliby WA, Dowdy SC, Bakkum-Gamez JN. Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0310","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ygyno.2015.08.026","article-title":"Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation","volume":"139","author":"Liu","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0315","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.07.095","article-title":"Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept","volume":"139","author":"Petrillo","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0320","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ygyno.2004.11.031","article-title":"Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study","volume":"96","author":"Fagotti","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0325","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0330","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0335","series-title":"Understanding and Optimizing the Potential Role of Surgical Debulking in Advanced Epithelial Ovarian Cancer","first-page":"e13","author":"du Bois","year":"2010"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055645","article-title":"Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention","volume":"8","author":"Eitan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0345","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0350","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0355","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2016.06.013_bb0360","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0365","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0370","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0375","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0380","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0385","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0390","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0395","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0400","doi-asserted-by":"crossref","unstructured":"L. Randall, R. Burger, H. Nguyen, G. Kong, M. Bookman, G. Fleming, B. Monk, R. Mannel, Birrer, M. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol. Oncol.2013;130: e33-e34.","DOI":"10.1016\/j.ygyno.2013.04.139"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0405","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0410","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0415","series-title":"NCCN Guideline Version 2.2015 Epithelial Ovarian Cancer\/Fallopian Tube Cancer\/Primary Pertoneal Cancer","author":"NCCN","year":"2015"},{"key":"10.1016\/j.ygyno.2016.06.013_bb0420","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0425","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2013.07.093","article-title":"Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?","volume":"131","author":"Perri","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0430","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0435","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2008.09.036","article-title":"Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review","volume":"112","author":"du Bois","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.013_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2016.03.037","article-title":"Targeting the hallmarks of ovarian cancer: the big picture","author":"Petrillo","year":"2016","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816308241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816308241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:38:52Z","timestamp":1600821532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816308241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0090825816308241"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.06.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}